Results 71 to 80 of about 1,019 (188)

Analysis of the German compassionate use program on spesolimab in patients with generalized pustular psoriasis: evidence outside of clinical trials [PDF]

Background Generalized pustular psoriasis (GPP) is a potentially life-threatening orphan disease. Interleukin (IL)-36 is a known pathogenetic key driver of GPP.
Hölsken, Stefanie, Krefting, Frederik, Kreuter, Alexander, Müller, Valentina Laura, Placke, Jan-Malte, Rueff, Franziska, Sondermann, Wiebke, Sticherling, Michael, Thamm, Janis, Thölken, Karisa, Welzel, Julia, Wohlrab, Johannes   +11 more
core   +1 more source

in-silico and in-vitro analysis of IL36RN mutations reveals critical residues for the function of the interleukin-36 receptor complex [PDF]

, 2023
Generalized pustular psoriasis (GPP) is a potentially life-threatening skin disease, associated with IL36RN mutations. IL36RN encodes the interleukin (IL)-36 receptor antagonist (IL-36Ra), a protein that downregulates the activity of IL-36 cytokines by ...
Capon, Francesca, Davan-Wetton, Camilla, Fakhreddine, Dana, Fraternali, Franca, Hassi, Niina K, Ng, Joseph C, Rinaldi, Giulia, Smahi, Asma, Twelves, Sophie, Weston, Timir   +9 more
core  

“Input/output cytokines” in epidermal keratinocytes and the involvement in inflammatory skin diseases [PDF]

, 2023
Considering the role of epidermal keratinocytes, they occupy more than 90% of the epidermis, form a physical barrier, and also function as innate immune barrier.
Kawakami, Yoshio, Morizane, Shin, Mukai, Tomoyuki, Ouchida, Mamoru, Sunagawa, Ko, Tachibana, Kota   +5 more
core   +1 more source

Dysregulated proteolytic cascades in Netherton syndrome: from molecular pathology to preclinical drug testing

The Journal of Pathology, EarlyView.
Abstract Netherton syndrome (NS) is a rare, severe, and often life‐threatening disease for which current therapeutic approaches are limited and show variable effectiveness. NS is characterized by excessive epidermal desquamation that results in a highly defective epidermal barrier, constitutive skin inflammation, allergies, and hair abnormalities.
Eleni Zingkou, Evangelos Bisyris, Georgios Pampalakis, Georgia Sotiropoulou   +3 more
wiley   +1 more source

Generalized pustular psoriasis : A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management [PDF]

, 2023
Generalized pustular psoriasis (GPP) is a rare and highly heterogeneous skin disease, characterized by flares of neutrophilic pustules and erythema. As a rare disease with few clinical studies and no standardized management approaches, there is a paucity
Choon, S.E., Gooderham, Melinda, Gottlieb, A.B., Marrakchi, S., Prinz, J.C., Puig Sanz, Lluís, Romiti, R., Tada, Yayoi, Universitat Autònoma de Barcelona, von Bredow, D.   +9 more
core   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

Journal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault, Emilie Brenaut, Marie‐Emeline Marniquet, Carla Berthault, Lea Canoen, Clarisse Marcombes, Audrey Melin, Raphaël Ouakrat, Julie Charles, Stephane Mouret, Olivier Potie, Laetitia Penso, Laura Pina Vegas, Guillaume Larid, Marine Roux, Colombe Bougeard, Sandy Sylvain, Clara Labonne, Tania Randriamiarana, Da Hee Pitaud, Floriane Etheve, Jeremy Gottlieb, Laurie Gouillon, Marine Chastagner, Emilie Sbidian, Hélène Aubert, on behalf of the Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie), Hélène Aubert, Marie Masson Regnault, Emilie Brenaut, Emilie Sbidian, Laura Pina Vegas, Laetitia Penso, Jeremy Gottlieb, Marine Roux, Clara Labonne, Tania Randriamiarana, Floriane Etheve, Da Hee Pitaud, Marie‐Emeline Marniquet, Carla Berthault, Clarisse Marcombes, Audrey Melin, Colombe Bougeard, Julie Charles, Olivier Potie, Léa Canoen, Laurie Gouillon, Marine Chastagner, Sandy Sylvain, Guillaume Larid, Raphaël Ouakrat   +51 more
wiley   +1 more source

Exploring the Clinical Assessment, Guidelines, and Options for the Treatment of Generalized Pustular Psoriasis [Podcast]

Clinical, Cosmetic and Investigational Dermatology, 2023
Eingun James Song,1,* Clive Liu2,* 1Frontier Dermatology, Mill Creek, Washington, USA; 2Bellevue Dermatology Clinic, Bellevue, Washington, USA*These authors contributed equally to this workCorrespondence: Dr Eingun James Song, Email Eingun.Song ...
Song EJ, Liu C
doaj  

Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study

SKIN The Journal of Cutaneous Medicine, 2023
Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory disorder characterized by painful inflammatory nodules (N), abscesses (A) and draining tunnels (dT), primarily affecting intertriginous areas. Interleukin-36 (IL-36) signaling has been notably expressed within HS inflammatory lesions. To address the need for targeted therapies, this
Afsaneh Alavi, Errol Prens, Alexa Kimball, James Krueger, Sutirtha Mukhopadhyay, Hui Wang, Nathalie Ivanhoff, Ana Cristina Hernandez, Christos Zouboulis   +8 more
openaire   +1 more source

Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies [PDF]

, 2023
Inflammatory bowel disease (IBD) is a term used to represent a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract. Crohn’s disease (CD) and ulcerative colitis (UC) are the two major clinical forms. The global incidence
Bretto, Elisabetta, Bugianesi, Elisabetta, Caviglia, Gian Paolo, Frara, Simone, Ribaldone, Davide Giuseppe, Saracco, Giorgio Maria   +5 more
core   +1 more source

Evolving Real‐World Data and Evidence Use for New Drugs and Regenerative Medical Products Approvals in Japan—An Analysis of the 6‐Year Trend

Clinical Pharmacology &Therapeutics, Volume 118, Issue 6, Page 1405-1421, December 2025.
Several regulatory initiatives have been made to clarify the acceptability and requirements of real‐world data and real‐world evidence (RWD/E) for the benefit/risk assessment of new medical products in Japan. The objectives of this review were to characterize the use of RWD/E in regulatory applications of new medical products and to describe the ...
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source